Read Summary

In the wake of the pivotal IDEA trial, oncologists have shifted towards shorter adjuvant chemotherapy regimens for stage III colon cancer and a greater reliance on CAPOX instead of FOLFOX.
Medscape Medical News

Print Friendly, PDF & Email